By: NewMediaWire
November 17, 2026
Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery
11,000+ Target Proteins - Reliable Supply - Built for AI-Driven Discovery
HOUSTON, TX - November 17, 2026 (NEWMEDIAWIRE) - As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development, access to well-characterized target proteins is essential for evaluating AI-designed molecules. Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global biotechnology company specializing in recombinant proteins, antibodies, and CRO services, introduces two dedicated target protein collections for AI-driven discovery: AI-Trusted Proteins and AI-Qualified Proteins.
Together, these collections offer researchers access to target proteins with demonstrated use in AI research, experimentally characterized binding activity, and specialized formats to support diverse AI-driven validation.
Two Collections. Two Ways to Support AI Validation.
AI-Trusted Proteins - Proven in AI Research
AI-Trusted Proteins have been used in AI-focused company validation projects, with some proteins featured in published research. This collection currently covers 600+ targets and 960+ individual proteins, with available characterization data for each protein potentially including SPR, BLI, ELISA, cell-based activity assays, SEC-HPLC, and SEC-MALS analyses.
AI-Qualified Proteins - Characterized for AI Validation
AI-Qualified Proteins feature experimentally characterized target binding activity, including SPR/BLI validation data, as well as specialized formats such as biotinylated proteins for AI-driven research. With 680+ targets and 1,700+ individual proteins, this collection provides researchers with a broad selection of characterized target proteins for evaluating AI-designed molecules.
The 4S System: Building Confidence in Target Protein Resources
Supporting these collections is Sino Biological's 4S System - Scale, Scope, Speed, and Supply, designed to provide the resource breadth, production capabilities, and supply reliability required by AI-driven discovery.
- Scale: More than 11,000 recombinant target proteins, including over 1,200 biotinylated proteins.
- Scope: Broad coverage of membrane, extracellular, and intracellular proteins, as well as mutants and diverse protein formats.
- Speed: Rapid, scalable production, efficient order processing, and local inventory and delivery capabilities.
- Supply: Lot-to-lot consistency, multi-lot availability, and reliable long-term supply.
Together, the 4S System helps researchers access a broad range of target proteins while supporting consistent experimental needs and ongoing AI research programs.
Sino Biological has also developed a therapeutic target directory covering 12 therapeutic areas and more than 100 diseases, enabling researchers to explore relevant targets by therapeutic area or disease.
4RISE™: Connecting Target Resources with End-to-End AI Validation
Target proteins are a critical part of experimental validation. As a key resource within Sino Biological's 4RISE™ AI Lab Validation Solution, the AI-focused target protein library works alongside high-throughput protein expression, binding and affinity characterization, developability assessment, and functional validation.
Built around four strengths - Rapid, In-Depth, Seamless, and Empirical - 4RISE™ provides integrated wet-lab support to help researchers advance AI-designed molecules from computational predictions to experimental evidence.
"AI-driven discovery depends on reliable experimental resources to evaluate designed molecules and guide subsequent research decisions," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. "By combining AI-Trusted and AI-Qualified target proteins with our 4S System, we aim to provide researchers with well-characterized target resources, broad coverage, and dependable supply to support AI-driven protein and antibody discovery."
About Sino Biological
Sino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and customized research services. Serving researchers in more than 90 countries, Sino Biological supports basic research, drug discovery, vaccine development, and diagnostics through its comprehensive product portfolio, proprietary quality systems, and innovative research platforms.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on Sino Biological management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Sino Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.
For media inquiries or partnership opportunities, please contact:
Sino Biological, Inc.
[email protected]
www.sinobiological.com
View the original release on www.newmediawire.com
This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery.

